CLINICAL TRIALS PROFILE FOR PAROXETINE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for PAROXETINE MESYLATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00786188 ↗ | Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause | Completed | Noven Therapeutics | Phase 2 | 2008-11-01 | This is an exploratory 8-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mgin subjects with moderate to severe postmenopausal vasomotor symptoms (VMS), defined as follows: - Moderate VMS: Sensation of heat with sweating, able to continue activity - Severe VMS: Sensation of heat with sweating, causing cessation of activity |
NCT01101841 ↗ | 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms | Completed | Noven Therapeutics | Phase 3 | 2010-03-01 | To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause |
NCT01361308 ↗ | Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) | Completed | Noven Therapeutics | Phase 3 | 2011-05-01 | The purpose of this study is to assess the safety & efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PAROXETINE MESYLATE
Condition Name
Clinical Trial Locations for PAROXETINE MESYLATE
Trials by Country
Clinical Trial Progress for PAROXETINE MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for PAROXETINE MESYLATE
Sponsor Name